- Home
- ACST vs ICCC Comparison
ACST vs ICCC Comparison
Compare ACST & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACST
- ICCC
- Stock Information
- Founded
- ACST 2002
- ICCC 1982
- Country
- ACST United States
- ICCC United States
- Employees
- ACST N/A
- ICCC N/A
- Industry
- ACST Pharmaceuticals and Biotechnology
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- ACST Health Care
- ICCC Health Care
- Exchange
- ACST Nasdaq
- ICCC Nasdaq
- Market Cap
- ACST 27.2M
- ICCC 28.7M
- IPO Year
- ACST N/A
- ICCC 1987
- Fundamental
- Price
- ACST $3.28
- ICCC $3.63
- Analyst Decision
- ACST Strong Buy
- ICCC
- Analyst Count
- ACST 2
- ICCC 0
- Target Price
- ACST $10.00
- ICCC N/A
- AVG Volume (30 Days)
- ACST 23.2K
- ICCC 22.8K
- Earning Date
- ACST 11-11-2024
- ICCC 11-13-2024
- Dividend Yield
- ACST N/A
- ICCC N/A
- EPS Growth
- ACST N/A
- ICCC N/A
- EPS
- ACST N/A
- ICCC N/A
- Revenue
- ACST N/A
- ICCC $23,222,929.00
- Revenue This Year
- ACST N/A
- ICCC N/A
- Revenue Next Year
- ACST N/A
- ICCC N/A
- P/E Ratio
- ACST N/A
- ICCC N/A
- Revenue Growth
- ACST N/A
- ICCC 48.05
- 52 Week Low
- ACST $1.98
- ICCC $3.34
- 52 Week High
- ACST $3.59
- ICCC $5.59
- Technical
- Relative Strength Index (RSI)
- ACST 60.89
- ICCC 48.07
- Support Level
- ACST $3.20
- ICCC $3.51
- Resistance Level
- ACST $3.44
- ICCC $3.74
- Average True Range (ATR)
- ACST 0.17
- ICCC 0.18
- MACD
- ACST 0.01
- ICCC 0.00
- Stochastic Oscillator
- ACST 70.08
- ICCC 36.05
About ACST Acasti Pharma Inc.
Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.